Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer

被引：0
|
作者：
Paul F. Schellhammer
Robert M. Hershberg
机构：
[1] Norfolk,Eastern Virginia Medical School and Devine Tidewater Urology
[2] Seattle,Dendreon Corporation
[3] 6333 Center Drive,Interstate Corporate Center
来源：
World Journal of Urology | 2005年 / 23卷
关键词：
Prostate cancer; Immunotherapy; Vaccine; Androgen independent; Provenge; Hormone refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express unique proteins which serve as highly specific targets. APC8015 (Provenge) is one such investigational therapeutic vaccine that uses autologous antigen presenting cells (APCs) loaded with a recombinant fusion protein of prostatic acid phosphatase linked to a molecule that specifically targets a receptor expressed on the surface of human APCs. Clinical trial outcomes have demonstrated activity in patients with androgen independent prostate cancer.
引用
收藏
页码：47 / 49
页数：2
相关论文
共 50 条
  • [41] ANDROGEN DEPRIVATION SELECTS FOR ANDROGEN INDEPENDENT, TUMOR-REINITIATING CELLS IN MODELS OF ANDROGEN DEPENDENT PROSTATE CANCER
    Germann, M.
    Wetterwald, A.
    Guzman, N.
    Williams, E.
    Cecchini, M. G.
    Thalmann, G. N.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 262 - 263
  • [42] Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
    Liu, Tiancheng
    Wu, Lisa Y.
    Fulton, Melody D.
    Johnson, Jacqueline M.
    Berkman, Clifford E.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (06) : 2087 - 2092
  • [43] Isolation and characterization of putative cancer stem cells from androgen independent prostate cancer
    Zeng, Gang
    Seiler, Daniel
    Liu, Gentao
    CANCER RESEARCH, 2008, 68 (09)
  • [44] Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells
    Blaszczyk, N
    Masri, BA
    Mawji, NR
    Ueda, T
    McAlinden, G
    Duncan, CP
    Bruchovsky, N
    Schweikert, HU
    Schnabel, D
    Jones, EC
    Sadar, MD
    CLINICAL CANCER RESEARCH, 2004, 10 (05) : 1860 - 1869
  • [45] Utility of serum prostate specific antigen doubling time (PSADT) in patients with androgen independent prostate cancer.
    Srinivas, S
    Balu, V
    King, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 410S - 410S
  • [46] The development of androgen-independent prostate cancer
    Brian J. Feldman
    David Feldman
    Nature Reviews Cancer, 2001, 1 : 34 - 45
  • [47] The Progression to Androgen-Independent Prostate Cancer
    Matusik, Robert J.
    JOURNAL OF ANDROLOGY, 2010, : 23 - 23
  • [48] Chemotherapy for androgen-independent prostate cancer
    Petrylak, DP
    WORLD JOURNAL OF UROLOGY, 2005, 23 (01) : 10 - 13
  • [49] Taxanes in metastatic androgen independent prostate cancer
    Barretina, Maria Pilar
    Jimenez, Laura
    Galan, Maica
    Laquente, Berta
    Perez, Xavier
    Encuentra, Maite
    Suarez, Francisco
    Boladeras, Ana
    Germa, Josep Ramon
    ANNALS OF ONCOLOGY, 2006, 17 : 156 - 156
  • [50] Chemotherapy for androgen-independent prostate cancer
    Daniel P. Petrylak
    World Journal of Urology, 2005, 23 : 10 - 13
12345